These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20703084)

  • 1. S-phase lengthening induced by p16(INK4a) overexpression in malignant cells with wild-type pRb and p53.
    Chien WW; Domenech C; Catallo R; Salles G; Ffrench M
    Cell Cycle; 2010 Aug; 9(16):3286-96. PubMed ID: 20703084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The atr protein kinase controls UV-dependent upregulation of p16INK4A through inhibition of Skp2-related polyubiquitination/degradation.
    Al-Khalaf HH; Hendrayani SF; Aboussekhra A
    Mol Cancer Res; 2011 Mar; 9(3):311-9. PubMed ID: 21270107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 1 expression is inhibited by p16(INK4a) at the post-transcriptional level through the microRNA pathway.
    Chien WW; Domenech C; Catallo R; Kaddar T; Magaud JP; Salles G; Ffrench M
    Oncogene; 2011 Apr; 30(16):1880-91. PubMed ID: 21170085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16CDKN2/INK4A.
    Fåhraeus R; Paramio JM; Ball KL; Laín S; Lane DP
    Curr Biol; 1996 Jan; 6(1):84-91. PubMed ID: 8805225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK4 inhibition restores G(1)-S arrest in MYCN-amplified neuroblastoma cells in the context of doxorubicin-induced DNA damage.
    Gogolin S; Ehemann V; Becker G; Brueckner LM; Dreidax D; Bannert S; Nolte I; Savelyeva L; Bell E; Westermann F
    Cell Cycle; 2013 Apr; 12(7):1091-104. PubMed ID: 23462184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of CDK7-carboxyl-terminal domain kinase activity by the tumor suppressor p16(INK4A) contributes to cell cycle regulation.
    Nishiwaki E; Turner SL; Harju S; Miyazaki S; Kashiwagi M; Koh J; Serizawa H
    Mol Cell Biol; 2000 Oct; 20(20):7726-34. PubMed ID: 11003668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.
    Ezhevsky SA; Nagahara H; Vocero-Akbani AM; Gius DR; Wei MC; Dowdy SF
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10699-704. PubMed ID: 9380698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4 and CDK6 delay senescence by kinase-dependent and p16INK4a-independent mechanisms.
    Ruas M; Gregory F; Jones R; Poolman R; Starborg M; Rowe J; Brookes S; Peters G
    Mol Cell Biol; 2007 Jun; 27(12):4273-82. PubMed ID: 17420273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
    Calbó J; Serna C; Garriga J; Graña X; Mazo A
    Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p16Ink4A, not only a G1 inhibitor?
    Dulić V
    Cell Cycle; 2010 Aug; 9(16):3150. PubMed ID: 20814232
    [No Abstract]   [Full Text] [Related]  

  • 13. E2F-1 but not E2F-4 can overcome p16-induced G1 cell-cycle arrest.
    Mann DJ; Jones NC
    Curr Biol; 1996 Apr; 6(4):474-83. PubMed ID: 8723352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G1 arrest by p16INK4A uncouples growth from cell cycle progression in leukemia cells with deregulated cyclin E and c-Myc expression.
    Ausserlechner MJ; Obexer P; Geley S; Kofler R
    Leukemia; 2005 Jun; 19(6):1051-7. PubMed ID: 15800668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK redundancy guarantees cell cycle progression in Rb-negative tumor cells independently of their p16 status.
    Santamariña M; Hernández G; Zalvide J
    Cell Cycle; 2008 Jul; 7(13):1962-72. PubMed ID: 18604173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells.
    Oruetxebarria I; Venturini F; Kekarainen T; Houweling A; Zuijderduijn LM; Mohd-Sarip A; Vries RG; Hoeben RC; Verrijzer CP
    J Biol Chem; 2004 Jan; 279(5):3807-16. PubMed ID: 14604992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term cultured IL-2-dependent T cell lines demonstrate p16(INK4a) overexpression, normal pRb/p53, and upregulation of cyclins E or D2.
    Siwicki JK; Hedberg Y; Nowak R; Lodén M; Zhao J; Landberg G; Roos G
    Exp Gerontol; 2000 May; 35(3):375-88. PubMed ID: 10832057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression.
    Lin YC; Diccianni MB; Kim Y; Lin HH; Lee CH; Lin RJ; Joo SH; Li J; Chuang TJ; Yang AS; Kuo HH; Tsai MD; Yu AL
    Oncogene; 2007 Oct; 26(49):7017-27. PubMed ID: 17486064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
    Fåhraeus R; Laín S; Ball KL; Lane DP
    Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
    Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
    Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.